Kejving Gustav, Sandén Gustav, Ljuslinder Ingrid, Rutegård Jörgen, Vinnars Petrus, Rutegård Martin
Department of Diagnostics and Intervention, Surgery, Umeå University, Umeå, Sweden.
Department of Diagnostics and Intervention, Oncology, Umeå University, Umeå, Sweden.
Colorectal Dis. 2025 Apr;27(4):e70104. doi: 10.1111/codi.70104.
Palliative rectal cancer patients typically retain their primary tumour, as trials have concluded no survival benefit of tumour resection in non-curative patients. This patient group is understudied regarding the natural course of the remaining tumour, particularly concerning the need of surgical management.
This was a retrospective study on rectal cancer patients diagnosed between 2007 and 2020 in Region Västerbotten, Sweden. Data were obtained from the Swedish Colorectal Cancer Registry and chart review. Patients were excluded if treated with curative intent, underwent primary tumour resection, had a synchronous colorectal cancer, had locally recurrent colorectal cancer, or refused treatment. Patients were followed from diagnosis until death or end of follow-up. Indications for palliative treatment, tumour-related complications and surgical and oncological management were investigated, with a stratified analysis for study period and patient age.
Some 156 patients remained after applying exclusion criteria. The majority had metastasized and incurable disease (76%). Almost half suffered local complications (44%) and 48% underwent surgical intervention, due to the unremoved primary tumour. Tumour perforation occurred in 7% with a significantly higher risk in patients aged ≤75 years (p = 0.009). Bowel obstruction afflicted 23%, while 40% underwent stoma diversion. Almost half received chemotherapy (48%) and radiotherapy (42%), respectively.
Rectal cancer patients with an unremoved primary tumour face a substantial risk of local complications, often necessitating surgical intervention. Therefore, the benefits of surgical resection should be carefully considered, especially for patients with a longer estimated survival. Further research is needed to accurately identify patients where tumour removal might be beneficial.
姑息性直肠癌患者通常保留其原发性肿瘤,因为试验得出结论,在无法治愈的患者中肿瘤切除并无生存益处。关于剩余肿瘤的自然病程,尤其是手术管理的必要性,这一患者群体的研究较少。
这是一项对2007年至2020年在瑞典韦斯特博滕地区诊断出的直肠癌患者的回顾性研究。数据来自瑞典结直肠癌登记处和病历审查。如果患者接受了根治性治疗、进行了原发性肿瘤切除、患有同步性结直肠癌、患有局部复发性结直肠癌或拒绝治疗,则将其排除。对患者从诊断开始进行随访,直至死亡或随访结束。调查了姑息治疗的指征、肿瘤相关并发症以及手术和肿瘤管理情况,并按研究时间段和患者年龄进行分层分析。
应用排除标准后,约有156名患者留存。大多数患者已发生转移且患有无法治愈的疾病(76%)。近一半患者出现局部并发症(44%),48%的患者因原发性肿瘤未切除而接受了手术干预。7%的患者发生肿瘤穿孔,年龄≤75岁的患者风险显著更高(p = 0.009)。23%的患者出现肠梗阻,40%的患者进行了造口改道。分别有近一半的患者接受了化疗(48%)和放疗(42%)。
原发性肿瘤未切除的直肠癌患者面临着较高的局部并发症风险,通常需要进行手术干预。因此,应仔细考虑手术切除的益处,尤其是对于预计生存期较长的患者。需要进一步研究以准确识别可能从肿瘤切除中获益的患者。